Viking Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) announced its participation in two investor conferences on March 7, 2023. Brian Lian, Ph.D., CEO, will engage in a fireside chat at the 35th Annual Roth Conference from March 12-14, 2023, at 2:30 p.m. PT on March 13. Additionally, Dr. Lian will present at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023, at 7:40 a.m. PT on March 14. A live webcast of the Oppenheimer presentation will be available on the Viking website. Viking focuses on developing therapies for metabolic and endocrine disorders, with three compounds in clinical trials, including VK2809 for NASH and VK2735 for metabolic disorders.

SAN DIEGO, March 7, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. 

Details of the company's participation are as follows:

• 35^th Annual Roth Conference
  Details: Brian Lian, Ph.D., Viking's chief executive officer, will participate in a fireside chat
  Conference Dates: March 12-14, 2023
  Fireside Chat Timing: 2:30 – 2:55 p.m. Pacific on Monday, March 13, 2023
  Location: The Ritz Carlton, Laguna Niguel in Dana Point, California
  
  
• Oppenheimer 33^rd Annual Healthcare Conference
  Details: Dr. Lian will deliver a corporate presentation
  Conference Dates: March 13-15, 2023
  Presentation Timing: 7:40 – 8:10 a.m. Pacific on Tuesday, March 14, 202
  Format: Virtual conference; webcast available

A live webcast of the Oppenheimer presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.  Additionally, a replay of the webcast will be available on the Viking website following the conferences.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-301762885.html

SOURCE Viking Therapeutics, Inc.

FAQ

What investor conferences will Viking Therapeutics (VKTX) participate in March 2023?

Viking Therapeutics will participate in the 35th Annual Roth Conference and the Oppenheimer 33rd Annual Healthcare Conference in March 2023.

When is Viking Therapeutics' fireside chat at the Roth Conference?

The fireside chat at the Roth Conference will take place on March 13, 2023, from 2:30 p.m. to 2:55 p.m. PT.

Where will the Oppenheimer Healthcare Conference be held?

The Oppenheimer Healthcare Conference will be a virtual conference from March 13-15, 2023.

What is the focus of Viking Therapeutics' clinical development?

Viking Therapeutics focuses on developing novel therapies for metabolic and endocrine disorders, with three compounds currently in clinical trials.

How can I access the live webcast of Viking Therapeutics' presentation?

The live webcast of the Oppenheimer presentation can be accessed via a link on the Viking Therapeutics website in the Investors & Media section.